Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
GLP-1RAS AND DIABETIC RETINOPATHY The phenomenon of worsening diabetic retinopathy (DR), often termed rebound retinopathy, is a well-established, paradoxical retinal finding linked to improved blood glucose levels, typically observed 3 months to 3 years after intense glucose lowering
Provider monitoring helps adjust your plan and reduce unnecessary side effects
These data, alongside other data being presented at ACC, reinforce the comprehensive set of health benefits of semaglutide, making it a strong option for healthcare professionals addressing the spectrum of metabolic and cardiovascular health and our continued leadership in the space. See citation- Bonaca MP, Catarig AM, Houlind K et al
Semaglutide for weight loss in patients with obesity: Doseresponse and injection site considerations
